Cargando…
MON-625 Serum Tsh Levels Normalisation In Patients With Celiac Disease After The Switch From Oral L-t4 In Tablet Form To L-t4 In Liquid Formulation
The absorption of L-thyroxine (L-T4) is influenced by several factors, such as patient’s age, drugs interference, absorption kinetics, dietary habits, adherence to therapy. Issues in the L-T4 absorption could be encountered by patients affected by celiac disease, because of drug malabsorption. We en...
Autores principales: | , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Endocrine Society
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6551142/ http://dx.doi.org/10.1210/js.2019-MON-625 |
_version_ | 1783424344507023360 |
---|---|
author | Ferrari, Silvia Martina Fallahi, Poupak Elia, Giusy Ragusa, Francesca Paparo, Sabrina Rosaria Caruso, Claudia Ruffilli, Ilaria Antonelli, Alessandro |
author_facet | Ferrari, Silvia Martina Fallahi, Poupak Elia, Giusy Ragusa, Francesca Paparo, Sabrina Rosaria Caruso, Claudia Ruffilli, Ilaria Antonelli, Alessandro |
author_sort | Ferrari, Silvia Martina |
collection | PubMed |
description | The absorption of L-thyroxine (L-T4) is influenced by several factors, such as patient’s age, drugs interference, absorption kinetics, dietary habits, adherence to therapy. Issues in the L-T4 absorption could be encountered by patients affected by celiac disease, because of drug malabsorption. We enrolled 22 patients with celiac disease and high serum thyrotropin (TSH) levels in treatment with L-T4 in tablet formulation. All subjects switched to a L-T4 liquid formulation, with no change in the dosage. A circulating TSH levels normalisation/reduction has been obtained in all the patients after the switch from L-T4 in tablet formulation to an oral liquid one with the same L-T4 dosage. Nine subjects switched back again to receive L-T4 in tablets (at the same dosage) reporting a worsening of TSH levels, and TSH values fell into the hypothyroid range. In conclusion, malabsorption issues could be overcome through oral L-T4 liquid formulation administration, in this way leading to ameliorate the management of patients affected by celiac disease. |
format | Online Article Text |
id | pubmed-6551142 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2019 |
publisher | Endocrine Society |
record_format | MEDLINE/PubMed |
spelling | pubmed-65511422019-06-13 MON-625 Serum Tsh Levels Normalisation In Patients With Celiac Disease After The Switch From Oral L-t4 In Tablet Form To L-t4 In Liquid Formulation Ferrari, Silvia Martina Fallahi, Poupak Elia, Giusy Ragusa, Francesca Paparo, Sabrina Rosaria Caruso, Claudia Ruffilli, Ilaria Antonelli, Alessandro J Endocr Soc Thyroid The absorption of L-thyroxine (L-T4) is influenced by several factors, such as patient’s age, drugs interference, absorption kinetics, dietary habits, adherence to therapy. Issues in the L-T4 absorption could be encountered by patients affected by celiac disease, because of drug malabsorption. We enrolled 22 patients with celiac disease and high serum thyrotropin (TSH) levels in treatment with L-T4 in tablet formulation. All subjects switched to a L-T4 liquid formulation, with no change in the dosage. A circulating TSH levels normalisation/reduction has been obtained in all the patients after the switch from L-T4 in tablet formulation to an oral liquid one with the same L-T4 dosage. Nine subjects switched back again to receive L-T4 in tablets (at the same dosage) reporting a worsening of TSH levels, and TSH values fell into the hypothyroid range. In conclusion, malabsorption issues could be overcome through oral L-T4 liquid formulation administration, in this way leading to ameliorate the management of patients affected by celiac disease. Endocrine Society 2019-04-30 /pmc/articles/PMC6551142/ http://dx.doi.org/10.1210/js.2019-MON-625 Text en Copyright © 2019 Endocrine Society https://creativecommons.org/licenses/by-nc-nd/4.0/ This article has been published under the terms of the Creative Commons Attribution Non-Commercial, No-Derivatives License (CC BY-NC-ND; https://creativecommons.org/licenses/by-nc-nd/4.0/). |
spellingShingle | Thyroid Ferrari, Silvia Martina Fallahi, Poupak Elia, Giusy Ragusa, Francesca Paparo, Sabrina Rosaria Caruso, Claudia Ruffilli, Ilaria Antonelli, Alessandro MON-625 Serum Tsh Levels Normalisation In Patients With Celiac Disease After The Switch From Oral L-t4 In Tablet Form To L-t4 In Liquid Formulation |
title | MON-625 Serum Tsh Levels Normalisation In Patients With Celiac Disease After The Switch From Oral L-t4 In Tablet Form To L-t4 In Liquid Formulation |
title_full | MON-625 Serum Tsh Levels Normalisation In Patients With Celiac Disease After The Switch From Oral L-t4 In Tablet Form To L-t4 In Liquid Formulation |
title_fullStr | MON-625 Serum Tsh Levels Normalisation In Patients With Celiac Disease After The Switch From Oral L-t4 In Tablet Form To L-t4 In Liquid Formulation |
title_full_unstemmed | MON-625 Serum Tsh Levels Normalisation In Patients With Celiac Disease After The Switch From Oral L-t4 In Tablet Form To L-t4 In Liquid Formulation |
title_short | MON-625 Serum Tsh Levels Normalisation In Patients With Celiac Disease After The Switch From Oral L-t4 In Tablet Form To L-t4 In Liquid Formulation |
title_sort | mon-625 serum tsh levels normalisation in patients with celiac disease after the switch from oral l-t4 in tablet form to l-t4 in liquid formulation |
topic | Thyroid |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6551142/ http://dx.doi.org/10.1210/js.2019-MON-625 |
work_keys_str_mv | AT ferrarisilviamartina mon625serumtshlevelsnormalisationinpatientswithceliacdiseaseaftertheswitchfromorallt4intabletformtolt4inliquidformulation AT fallahipoupak mon625serumtshlevelsnormalisationinpatientswithceliacdiseaseaftertheswitchfromorallt4intabletformtolt4inliquidformulation AT eliagiusy mon625serumtshlevelsnormalisationinpatientswithceliacdiseaseaftertheswitchfromorallt4intabletformtolt4inliquidformulation AT ragusafrancesca mon625serumtshlevelsnormalisationinpatientswithceliacdiseaseaftertheswitchfromorallt4intabletformtolt4inliquidformulation AT paparosabrinarosaria mon625serumtshlevelsnormalisationinpatientswithceliacdiseaseaftertheswitchfromorallt4intabletformtolt4inliquidformulation AT carusoclaudia mon625serumtshlevelsnormalisationinpatientswithceliacdiseaseaftertheswitchfromorallt4intabletformtolt4inliquidformulation AT ruffilliilaria mon625serumtshlevelsnormalisationinpatientswithceliacdiseaseaftertheswitchfromorallt4intabletformtolt4inliquidformulation AT antonellialessandro mon625serumtshlevelsnormalisationinpatientswithceliacdiseaseaftertheswitchfromorallt4intabletformtolt4inliquidformulation |